Ipsen | Key People and Executives
Marc M. P. de Garidel
Non-Executive Chairman
David D. Meek
Chief Executive Officer & Director
Christophe Vérot
Director
Philippe Bonhomme
Director
Antoine Flochel
Vice Chairman
Margaret A. Liu
Independent Director
Carol Stuckley
Independent Director
Michèle Ollier
Independent Director
Hélène Auriol-Potier
Independent Director
Hervé Couffin
Independent Director
Pierre Martinet
Independent Director
Marc M. P. de Garidel
Non-Executive Chairman
David D. Meek
Chief Executive Officer & Director
Aymeric Le Chatelier
Chief Financial Officer & Executive Vice President
Aidan Murphy
Executive Vice President-Technical Operations
Alexandre P. LeBeaut
Chief Scientific Officer
Sotirios G. Stergiopoulos
Chief Medical Officer
Benoit Hennion
Executive VP & President-Consumer Healthcare
Dominique Bery
Executive Vice President-Strategy & Transformation
Dominique Laymand
Senior VP, Chief Ethics & Compliance Officer
Ivana Magovcevic-Liebisch
Chief Business Officer & Executive Vice President
Christophe Vérot
Director
Philippe Bonhomme
Director
Antoine Flochel
Vice Chairman
Heather White
Vice President-Global Internal Audit
Ian Weatherhead
Vice President-Corporate External Communications
Didier Véron
SVP-Public Affairs & Corporate Communications
Eugenia Litz
Vice President-Investor Relations
Regis Mulot
Chief Human Resources Officer & Executive VP
François Garnier
Executive Vice President & General Counsel
Margaret A. Liu
Independent Director
Carol Stuckley
Independent Director
Michèle Ollier
Independent Director
Hélène Auriol-Potier
Independent Director
Hervé Couffin
Independent Director
Pierre Martinet
Independent Director
| Address |
65, quai Georges Gorse
Boulogne-Billancourt Ile-de-France 92650
France
|
|
Employees
|
- |
| Website |
http://www.ipsen.com |
| Updated |
07/08/2019 |
| Ipsen SA manufactures pharmaceutical products for oncology, neuroscience and rare diseases. It operates through following segments: Specialty Care and Consumer Healthcare. The Specialty Care segment focuses on Oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and Rare Diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin. |
